Nothing Special   »   [go: up one dir, main page]

Kijewski et al., 2016 - Google Patents

Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated

Kijewski et al., 2016

View HTML
Document ID
4459910723788668151
Author
Kijewski S
Akiyama H
Feizpour A
Miller C
Ramirez N
Reinhard B
Gummuluru S
Publication year
Publication venue
Virology

External Links

Snippet

The mechanisms behind the low viral loads and lower mortality rates of HIV-2+ individuals remain unknown. We hypothesized that reduced interaction of HIV-2 with CD169, the primary HIV-1 attachment factor on monocyte-derived dendritic cells (DCs) that targets …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—AIDS or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Akiyama et al. CD169-mediated trafficking of HIV to plasma membrane invaginations in dendritic cells attenuates efficacy of anti-gp120 broadly neutralizing antibodies
Hatch et al. Glycosphingolipid composition of human immunodeficiency virus type 1 (HIV-1) particles is a crucial determinant for dendritic cell-mediated HIV-1 trans-infection
US9789130B2 (en) Method for blocking HIV entry into dendritic cells by inhibiting sialoadhesin-sialyllactose binding interactions with gangliosides
Kijewski et al. Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated
Altaf 232 Explosive Expansion of HIV and associated risk factors among Male and Hijra Sex Workers in Sindh, Pakistan
Sundaram 204 Serum albumin: Could it be an inexpensive and simple marker of immunosupression in HIV-infected individuals?
Kijewski Mechanistic differences in interactions of HIV-1 and HIV-2 with dendritic cells
Onigbogi 138 Prevalence of Human Papillomavirus (HPV) Infection among HIV-positive women in the Pre-HAART and HAART era in a Nigerian Clinic
Kim Expression of Globotriaosylceramide in Human CD4+ T-cells
Monaco et al. 183 Morphogenomic immune responsiveness to preventive/therapeutic vaccines
Subramanya 213 Dendritic cell-specific delivery of siRNA targeting SOCS1 enhances HIV-gag-specific CD8 T cell response
Vidya et al. 238 Comparative Evaluation of the Performance of Abbott m2000rt Real-Time HIV-1 Assay for Measurement of HIV-1 Plasma Viral Load
Dalgleish et al. 174 The C5 region of gp120: A therapeutic vaccine target?
Choudhary et al. 234 Neutralization efficiency and presence of anti-V3 antibodies in plasma of HIV-1 infected Northern Indians
Nakimuli-Mpungu 228 Psychological distress as a risk factor for non-adherence to Highly active anti-retroviral\therapy
Yuste et al. 226 Glycosylation of gp41 of Simian Immunodeficiency Virus Shields Epitopes That Can Be Targets for Neutralizing Antibodies
Jaffee 177 Recruitment of high avidity antigen-specific T cells in pancreatic cancer patients
Mulenga et al. 229 Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia
Klein 149 The role of the microenvironment in EBV associated lymphoid malignancies
Gupta et al. 242 Mycobacterium avium KatG protein (MAV_2753): a putative candidate for the serodiagnosis of MAC disease
Daniels et al. 130 Inhibition of HIV-1 Release by Cell Permeable Peptides
Honghong 263 Adherence to highly active antiretroviral treatment and related factors in drug users with HIV/AIDS
Leite et al. 203 Immunosuppression Level In HIV-1-Infected Patients Doesn't Affect the Serological Diagnosis of Hepatitis C Virus
Garcia-Martinez 156 Humanized Mouse Models for The In Vivo Analysis of HIV Infection
Ganem 151 MicroRNAs and the biology of KSHV infection